Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
Open accessAbstract
Alemtuzumab for Immune-Related Myocarditis Myocarditis after the use of immune checkpoint inhibitors is a potentially fatal complication. Immune suppression with glucocorticoids is often effective ...
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In steroid-refractory ICI myocarditis, abatacept, alemtuzumab, and antithymocyte globulin have been used in case reports.
“In cases refractory to steroids, other immunomodulators, including abatacept (a CTLA-4 agonist), alemtuzumab (anti-CD52 antibody), and antithymocyte globulin (antiCD3 antibody) have been used in case reports.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [261]
In the letter “Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy” (page not supplied), the authors report giving alemtuzumab after a flare during maximal immunosuppression for checkpoint-inhibitor myocarditis. The copy supports alemtuzumab as a case-report example and identifies it as binding CD52, but it does not report use of abatacept or antithymocyte globulin. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942 · see citing works
Immune Checkpoint Inhibitor-Associated Myocarditis
Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 301 · see citing works
Hughes, M., Lilleker, J. B., Herrick, A. L., & Chinoy, H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206812 · Cited by 95 · see citing works
Alemtuzumab for Cytolytic Induction of Immunosuppression in Heart Transplant Recipients
Cahoon, W. D., Ensor, C. R., & Shullo, M. A. (2012) · Progress in Transplantation · doi:10.7182/pit2012241 · Cited by 15 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Schneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,434 · see citing works
Immune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,447 · see citing works
Haanen, J. B. A. G., Obéid, M., Spain, L. A., Carbonnel, F., Wang, Y.-S., Robert, C., Lyon, A. R., Wick, W., Kostine, M., Peters, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.001 · Cited by 1,386 · see citing works
Immune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982 · see citing works
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917 · see citing works
Ammirati, E., Frigerio, M., Adler, E. D., Basso, C., Birnie, D. H., Brambatti, M., Friedrich, M. G., Klingel, K., Lehtonen, J., Moslehi, J. J., et al. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.120.007405 · Cited by 811 · see citing works
Kociol, R. D., Cooper, L. T., Fang, J. C., Moslehi, J. J., Pang, P. S., Sabe, M. A., Shah, R. V., Sims, D. B., Thiene, G., Vardeny, O., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000745 · Cited by 625 · see citing works
Palaskas, N., Lopez‐Mattei, J., Durand, J. B., Iliescu, C., & Deswal, A. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013757 · Cited by 535 · see citing works
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Thompson, J. A., Schneider, B. J., Brahmer, J. R., Andrews, S., Armand, P. A., Bhatia, S., Budde, L. E., Costa, L. J., Davies, M. J., Dunnington, D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0012 · Cited by 488 · see citing works
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351 · see citing works
Self-citationChoi, J., & Lee, S. Y. (2020) · Immune Network · doi:10.4110/in.2020.20.e9 · Cited by 304 · see citing works
Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze‐Koops, H., Choy, E., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 301 · see citing works
Alexandre, J., Cautela, J., Éderhy, S., Damaj, G. L., Salem, J., Barlési, F., Farnault, L., Charbonnier, A., Mirabel, M., Champiat, S., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018403 · Cited by 296 · see citing works
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237 · see citing works
Pathak, R., Katel, A., Massarelli, E., Villaflor, V. M., Sun, V. C.-Y., & Salgia, R. (2021) · The Oncologist · doi:10.1002/onco.13931 · Cited by 223 · see citing works
Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis
Ma, P., Liu, J., Qin, J., Lai, L., Heo, G. S., Luehmann, H., Sultan, D., Bredemeyer, A., Bajapa, G., Feng, G., et al. (2024) · Circulation · doi:10.1161/circulationaha.122.062551 · Cited by 187 · see citing works
Lehmann, L. H., Cautela, J., Palaskas, N., Baik, A. H., Meijers, W. C., Allenbach, Y., Alexandre, J., Rassaf, T., Müller, O. J., Aras, M., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2241 · Cited by 178 · see citing works
Immune-related adverse events in various organs caused by immune checkpoint inhibitors
Okiyama, N., & Tanaka, R. (2022) · Allergology International · doi:10.1016/j.alit.2022.01.001 · Cited by 164 · see citing works
Ammirati, E., Veronese, G., Bottiroli, M., Wang, D. W., Cipriani, M., Garascia, A., Pedrotti, P., ADLER, E. D., & Frigerio, M. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.05.008 · Cited by 153 · see citing works
Cardiotoxicity of Immune Checkpoint Inhibitors
Patel, R. P., Parikh, R. B., Gunturu, K. S., Tariq, R. Z., Dani, S. S., Ganatra, S., & Nohria, A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01070-6 · Cited by 152 · see citing works
Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N. L., & Neilan, T. G. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.11.012 · Cited by 145 · see citing works
Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors
Aldrich, J. D., Pundole, X., Tummala, S., Palaskas, N. L., Andersen, C. R., Shoukier, M., Abdel‐Wahab, N., Deswal, A. M., & Suarez-Almazor, M. E. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41604 · Cited by 133 · see citing works
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 130 · see citing works
Cardiotoxicity from immune checkpoint inhibitors
Michel, L., Rassaf, T., & Totzeck, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100420 · Cited by 125 · see citing works
Autoimmune complications of immunotherapy: pathophysiology and management
Chan, K. K., & Bass, A. R. (2020) · BMJ · doi:10.1136/bmj.m736 · Cited by 125 · see citing works
Johnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30107-8 · Cited by 118 · see citing works
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
Shalata, W., Abu-Salman, A., Steckbeck, R., Jacob, B. M., Massalha, I., & Yakobson, A. (2021) · Cancers · doi:10.3390/cancers13205218 · Cited by 108 · see citing works
Gu, X., Li, Y., Chen, K., Wang, X., Wang, Z., Lian, H., Lin, Y., Rong, X., Chu, M., Lin, J., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15378 · Cited by 105 · see citing works
Zhou, Y., Zhu, Y., Wang, M., Xie, Y., Chen, C.-Y., Zhang, T., Xia, F., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01350 · Cited by 101 · see citing works
Cautela, J., Zeriouh, S., Gaubert, M., Bonello, L., Laine, M., Peyrol, M., Paganelli, F. F., Lalevée, N., Barlési, F., & Thuny, F. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001887 · Cited by 96 · see citing works
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance
Géraud, A., Gougis, P., Vozy, A., Anquetil, C., Allenbach, Y., Romano, E., Funck‐Brentano, E., Moslehi, J. J., Johnson, D. B., & Salem, J. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022820-093805 · Cited by 94 · see citing works
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Munir, A. Z., Gutierrez, A., Qin, J., Lichtman, A. H., & Moslehi, J. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00715-5 · Cited by 94 · see citing works
Adverse events induced by immune checkpoint inhibitors
Perdigoto, A. L., Kluger, H. M., & Herold, K. C. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.002 · Cited by 77 · see citing works
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
Doms, J., Prior, J. O., Peters, S., & Obéid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.005 · Cited by 76 · see citing works
Corticosteroid-resistant immune-related adverse events: a systematic review
Daetwyler, E., Wallrabenstein, T., König, D., Cappelli, L. C., Naidoo, J., Zippelius, A., & Laubli, H. P. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007409 · Cited by 76 · see citing works
Sławiński, G., Wrona, A., Dąbrowska-Kugacka, A., Raczak, G., & Lewicka, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197195 · Cited by 74 · see citing works
Lipe, D. N., Qdaisat, A. Z., Krishnamani, P. P., Nguyen, T. D., Chaftari, P. S., Messiri, N. E., Srinivasan, A., Galvis-Carvajal, E., Reyes‐Gibby, C. C., & Wattana, M. K. (2024) · Diagnostics · doi:10.3390/diagnostics14161794 · Cited by 69 · see citing works
Quagliariello, V., Passariello, M., Rea, D., Barbieri, A., Iovine, M., Bonelli, A., Caronna, A., Botti, G., Lorenzo, C. D., & Maurea, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040179 · Cited by 67 · see citing works
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
Pirozzi, F., Poto, R., Aran, L., Cuomo, A., Galdiero, M. R., Spadaro, G., Abete, P., Bonaduce, D., Marone, G., Tocchetti, C. G., et al. (2021) · Current Oncology Reports · doi:10.1007/s11912-020-01002-w · Cited by 66 · see citing works
Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases
Zotova, L. (2023) · Diagnostics · doi:10.3390/diagnostics13071243 · Cited by 64 · see citing works
Wang, C., Lin, J., Wang, Y., Hsi, D. H., Chen, J., Liu, T., Zhou, Y., Ren, Z., Zeng, Z., Cheng, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.770631 · Cited by 62 · see citing works
Xing, Q., Zhang, Z., Lin, Q., Shen, L., Wang, P., Zhang, S., Fan, M., & Zhu, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.79 · Cited by 62 · see citing works
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
Cozma, A., Sporiș, N.-D., Lazăr, A.-L., Buruiană, A., Ganea, A.-M., Mălinescu, T.-V., Berechet, B. M., Fodor, A., Sitar-Tăut, A., Vlad, C. V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810948 · Cited by 60 · see citing works
Cardiotoxicity of Contemporary Anticancer Immunotherapy
Dalbo, N., Patel, R. P., Parikh, R. B., Shah, S. P., Guha, A., Dani, S. S., & Ganatra, S. (2020) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00867-1 · Cited by 59 · see citing works
Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis
Ammirati, E., Bizzi, E., Veronese, G., Groh, M., Heyning, C. M. V. D., Lehtonen, J. Y. A., de Chambrun, M. P., Cereda, A. F., Picchi, C., Trotta, L., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.838564 · Cited by 59 · see citing works
Valencia-Sánchez, C., & Ζεκερίδου, Α. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.642800 · Cited by 58 · see citing works
PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
Safi, M., Ahmed, H., Al‐Azab, M., Xia, Y., Shan, X., Alradhi, M., Al-Danakh, A., Shopit, A., & Liu, J. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.09.006 · Cited by 56 · see citing works
Management of Cardiac Toxicity Induced by Chemotherapy
Trapani, D., Zagami, P., Nicolò, E., Pravettoni, G., & Curigliano, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092885 · Cited by 56 · see citing works
Arangalage, D., Degrauwe, N., Michielin, O. A., Monney, P. A., & Özdemir, B. C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102282 · Cited by 56 · see citing works
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55 · see citing works
Peripheral nervous system immune-related adverse events due to checkpoint inhibition
O’Hare, M., & Guidon, A. C. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01001-6 · Cited by 54 · see citing works
Cardiovascular toxicity of immune therapies for cancer
Palaskas, N. L., Ali, H.-J., Koutroumpakis, E., Ganatra, S., & Deswal, A. M. (2024) · BMJ · doi:10.1136/bmj-2023-075859 · Cited by 53 · see citing works
Autoimmune Myocarditis, Old Dogs and New Tricks.
Won, T., Song, E. J., Kalinoski, H. M., Moslehi, J. J., & Čiháková, D. (2024) · Circulation Research · doi:10.1161/circresaha.124.323816 · Cited by 51 · see citing works
Berg, M. H., Rincon, S. V. D., & Miller, W. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003551 · Cited by 51 · see citing works
Self-citationDiretriz de Miocardites da Sociedade Brasileira de Cardiologia – 2022
Montera, M. W., Marcondes‐Braga, F. G., Simões, M. V., Moura, L. Z., Fernandes, F., Mangini, S., de Oliveira, A. C., de Souza, A. L. A. D. A. G., Ianni, B. M., Rochitte, C. E., et al. (2022) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20220412 · Cited by 51 · see citing works
Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis
Huang, Y. V., Sun, Y., Chou, H., Wagner, N., Vitale, M. R., Bayer, A. L., Xu, B., Lee, D. C., Lin, Z., Branche, C., et al. (2025) · Circulation Research · doi:10.1161/circresaha.124.325652 · Cited by 50 · see citing works
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Raschi, E., Rossi, S., Giglio, A. D., Fusaroli, M., Burgazzi, F., Rinaldi, R., & Potena, L. (2023) · Drug Safety · doi:10.1007/s40264-023-01320-5 · Cited by 47 · see citing works
Guo, X., Chen, S., Wang, X., & Liu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138483 · Cited by 46 · see citing works
Matzen, E., Bartels, L. E., Løgstrup, B. B., Madsen, S. H., Stilling, C., & Donskov, F. N. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00114-x · Cited by 45 · see citing works
Baik, A. H., Tsai, K. K., Oh, D. Y., & Aras, M. A. (2021) · Clinical Science · doi:10.1042/cs20200331 · Cited by 42 · see citing works
Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy
Xu, J., Brosseau, J., & Shi, H. (2020) · Oncogene · doi:10.1038/s41388-020-01491-w · Cited by 41 · see citing works
Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
Tomsitz, D., Ruf, T., Zierold, S., French, L. E., & Heinzerling, L. M. (2023) · Cancers · doi:10.3390/cancers15092538 · Cited by 40 · see citing works
Plasma Exchange for Immune Checkpoint Inhibitor–Induced Myocarditis
Yogasundaram, H., Alhumaid, W., Chen, J. W., Church, M., Alhulaimi, N., Kimber, S., Paterson, D. I., & Senaratne, J. M. (2020) · CJC Open · doi:10.1016/j.cjco.2020.11.004 · Cited by 40 · see citing works
Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
Kawashima, S., Joachim, K., Abdelrahim, M., Abudayyeh, A., Jhaveri, K. D., & Murakami, N. (2022) · Korean Journal of Transplantation · doi:10.4285/kjt.22.0013 · Cited by 39 · see citing works
Therapeutic strategies for virus-negative myocarditis: a comprehensive review
Luca, G. D. D., Campochiaro, C., Sartorelli, S., Peretto, G., & Dagna, L. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.050 · Cited by 38 · see citing works
Liu, S., Chan, J., Brinc, D., Gandhi, S., Izenberg, A., Delgado, D., Abdel-Qadir, H. M., Wintersperger, B. J., & Thavendiranathan, P. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.10.013 · Cited by 37 · see citing works
Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives
Bohdan, M., Kowalczys, A., Mickiewicz, A., Gruchała, M., & Lewicka, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081647 · Cited by 37 · see citing works
Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review
Filho, P. N., Albuquerque, C., Capella, M. P., & Debiasi, M. (2023) · Oncology and Therapy · doi:10.1007/s40487-023-00224-9 · Cited by 35 · see citing works
Management perspectives from the 2019 Wuhan international workshop on fulminant myocarditis
Veronese, G., Ammirati, E., Chen, C., Klingel, K., Suzuki, M., Okumura, T., Maisch, B., Zuo, H., Ni, L., Jiang, J., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.10.063 · Cited by 34 · see citing works
Zhang, R. S., Padegimas, A., Murphy, K. M., Evans, P. T., Peters, C. J., Domenico, C. M., Vidula, M. K., Mather, P. J., Cevasco, M., Cohen, R. B., et al. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00095-x · Cited by 34 · see citing works
Jiang, J., Shu, H., Wang, D. W., Hui, R., Li, C., Ran, X., Wang, H., Zhang, J., Nie, S., Cui, G., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2421-0 · Cited by 33 · see citing works
Liu, X., Wu, W., Fang, L., Liu, Y., & Chen, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.922782 · Cited by 32 · see citing works
Weill, A., Delyon, J., Descamps, V., Deschamps, L., Dinulescu, M., Dupuy, A., Celérier, P., Nardin, C., Aubin, F., Corre, Y. L., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/keab249 · Cited by 31 · see citing works
Deleterious Role of Th9 Cells in Pulmonary Fibrosis
Deng, K., Yang, X. S., Luo, Q., She, Y. X., Yu, Q. Y., & Tang, X. X. (2021) · Cells · doi:10.3390/cells10113209 · Cited by 31 · see citing works
Zito, C., Manganaro, R., Ciappina, G., Spagnolo, C. C., Racanelli, V., Santarpía, M., Silvestris, N., & Carerj, S. (2022) · Cancers · doi:10.3390/cancers14215403 · Cited by 31 · see citing works
Current Treatment and Immunomodulation Strategies in Acute Myocarditis
Ferone, E., Segev, A., Tempo, E., Gentile, P., Elsanhoury, A., Baggio, C., Artico, J., Bhatti, P., Scott, P. A., Bobbio, E., et al. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001542 · Cited by 29 · see citing works
Liang, S., Yang, J., Lin, Y. P., Li, T., Zhao, W., Zhao, J., & Dong, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.682262 · Cited by 29 · see citing works
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
Ronen, D., Bsoul, A., Lotem, M., Abedat, S., Yarkoni, M., Amir, O., & Asleh, R. (2022) · Vaccines · doi:10.3390/vaccines10040540 · Cited by 28 · see citing works
Dong, H., Qi, Y., Kong, X., Wang, Z., Fang, Y., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835510 · Cited by 28 · see citing works
Sun, J.-Y., Qu, Q., Lou, Y.-X., Yang, H., Sun, G.-Z., Sun, W., & Kong, X. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.09.041 · Cited by 27 · see citing works
Gong, J., Neilan, T. G., & Zlotoff, D. A. (2023) · Immunological Reviews · doi:10.1111/imr.13240 · Cited by 26 · see citing works
Diagnosis, risk stratification and management of myocarditis
Müller, M., Cooper, L. T., & Heidecker, B. (2021) · Heart · doi:10.1136/heartjnl-2021-319027 · Cited by 26 · see citing works
Immune checkpoint inhibitor–associated myocarditis: a systematic analysis of case reports
Wang, C., Zhao, G., Zhang, Z., Yang, L., Liu, S., Li, G., Wang, H., Huang, J., Wang, S., & Li, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1275254 · Cited by 25 · see citing works
Tocilizumab for Fulminant Programmed Death 1 Inhibitor–Associated Myocarditis
Wang, H., Tian, R., Gao, P., Wang, Q., & Zhang, L. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.080 · Cited by 25 · see citing works
Deharo, F., Carvelli, J., Cautela, J., Garcia, M., Sarles, C., de Paula, A. M., Bourenne, J., Gainnier, M., & Bichon, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195611 · Cited by 24 · see citing works
Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
Zadok, O. I. B., Ben‐Avraham, B., Nohria, A., Orvin, K., Nassar, M., Iakobishvili, Z., Neiman, V., Goldvaser, H., Kornowski, R., & Gal, T. B. (2019) · JACC CardioOncology · doi:10.1016/j.jaccao.2019.07.004 · Cited by 23 · see citing works
Immune checkpoint inhibitor-associated cardiovascular toxicities: A review
Liu, G., Chen, T., Zhang, X., Hu, B., & Shi, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25747 · Cited by 22 · see citing works
Anti-inflammatory pharmacotherapy in patients with cardiovascular disease
Finocchiaro, S., Mazzone, P. M., Ammirabile, N., Bordonaro, C., Cusmano, C., Cutore, L., Leo, G. D., Faro, D. C., Giacoppo, D., Greco, A., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf058 · Cited by 21 · see citing works
Immune Checkpoint Inhibitors and Infection: What Is the Interplay?
Papadakis, M., Karniadakis, I., Mazonakis, N., Akinosoglou, K., Tsioutis, C., & Spernovasilis, N. A. (2023) · In Vivo · doi:10.21873/invivo.13346 · Cited by 21 · see citing works
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review
Upshaw, J. N. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00923-w · Cited by 21 · see citing works
Gürdoğan, M. (2020) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2020.79584 · Cited by 21 · see citing works
Bai, J., Li, D., Yang, P., Xu, K., Wang, Y., Li, Q., Liu, J., Du, W., Zhang, F., & Feng, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.778185 · Cited by 21 · see citing works
Drug therapy for myocarditis induced by immune checkpoint inhibitors
Wu, Y., Xu, Y., & Xu, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1161243 · Cited by 20 · see citing works
Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system
Michel, L., Totzeck, M., Lehmann, L., & Finke, D. (2020) · Herz · doi:10.1007/s00059-020-04954-8 · Cited by 19 · see citing works
Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events
Kadowaki, H., Akazawa, H., Ishida, J., & Komuro, I. (2021) · JMA Journal · doi:10.31662/jmaj.2021-0001 · Cited by 19 · see citing works
Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review
Madanat, L., Gupta, R., Weber, P., Kumar, N., Chandra, R., Ahaneku, H. P., Bansal, Y., Anderson, J., Bilolikar, A., & Jaiyesimi, I. A. (2022) · Current Cardiology Reviews · doi:10.2174/1573403x18666220531094800 · Cited by 19 · see citing works
An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors
Esposito, R., Fedele, T., Orefice, S., Cuomo, V., Prastaro, M., Canonico, M. E., Ilardi, F., Stefano, F. D., Fiorillo, L., Santoro, C., et al. (2021) · Biomolecules · doi:10.3390/biom11060785 · Cited by 18 · see citing works
Zarifa, A., Kim, J. W., Lopez‐Mattei, J., Palaskas, N. L., Iliescu, C., & Kim, P. Y. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2021.0089 · Cited by 17 · see citing works
Analysis of clinical characteristics of mesalazine-induced cardiotoxicity
Chen, J., Duan, T., Fang, W., Liu, S., & Wang, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.970597 · Cited by 17 · see citing works
Treatment of Immune Checkpoint Inhibitor-associated Myocarditis
Heemelaar, J. C., Louisa, M., & Neilan, T. G. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001456 · Cited by 17 · see citing works
- Authors
- Esfahani, K., Buhlaiga, N., Thébault, P., Lapointe, R., Johnson, N. A., & Miller, W. H.
- Affiliations
- McGill University (CA)
- Université de Montréal (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-06-13
- Volume
- 380
- Issue
- 24
- Pages
- 2375-2376
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2949277199
- Semantic Scholar
- 2f103e1c787c09bd77b6e74d1aecb2033ee5284e
- Cited by
- 224
- References
- 4
- Citations by year
- 2026: 19 · 2025: 14 · 2024: 29 · 2023: 31 · 2022: 36 · 2021: 37 · 2020: 46 · 2019: 9
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
- Keywords
- alemtuzumab, immune-related myocarditis, PD-1 inhibitors, immune checkpoint inhibitors, immune-related adverse events, glucocorticoid-induced immunosuppression, cardiotoxicity
- MeSH terms
- Antineoplastic Agents, Immunological, Alemtuzumab, Aged, Arrhythmias, Cardiac, Female, Humans, Melanoma, Myocarditis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
